Synexo Group
$3.5M enterprise value. 100% ARR growth, 119% NRR, and an acquisition pipeline 17x the size of current revenues.
A Random Walk Down Micro Street
A newsletter devoted to sharing my research on various microcap companies. These are the companies that Wall Street analysts has never heard of. Let's find them before they do.
Subscribe:.rss.atom.json.md.m3u.pls
Live Last read · last published · next check
Latest episodes
Update: Sanara Medtech
Three and a half years after the original write-up, it's time for an update
LQDA: Litigation Overhang Creates Opportunity
Liquidia Corp is a biopharmaceutical company focused on pulmonary arterial hypertension (PAH). PAH is a rare, chronic, progressive disease caused by hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death, with an estimated prevalence in the United States of approximately 30,000 patients
Sanara MedTech (SMTI)
A High Margin, High Growth Opportunity